|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis.
|
31123339 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Dupilumab-mediated inhibition of IL-4/IL-13 signaling through IL-4 receptor α blockade significantly and progressively improved disease activity, suppressed cellular/molecular cutaneous markers of inflammation and systemic measures of type 2 inflammation, and reversed AD-associated epidermal abnormalities.
|
30194992 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Researchers have shown that patch testing is safe and effective in afflicted children and that those with atopic dermatitis (AD) have similar sensitization rates, although they have a higher sensitization to certain allergens, thought to be related to the inflammatory (IL-4) milieu.
|
30225535 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
As a result of their structural similarity, interleukin-13 and interleukin-4 have overlapping functions in the mediation of type-II-driven diseases and are, therefore, promising targets of biologic drugs currently in development for the treatment of such diseases, including asthma and atopic dermatitis.
|
29411337 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, gracillin strongly inhibited PI-induced IL-4 expression in RBL-2H3 cells and in the skins of AD mice.
|
30200442 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Atopic dermatitis (AD) is a complex chronic pruritic skin disease in which helper T cell (TH2)-type cytokines IL-4 and IL-13 are key contributors in the inflammatory response.
|
30372706 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared with control subjects, skin lesions from AD animal models exhibited significantly reduced epidermal and dermal thicknesses, as well as reduced messenger ribonucleic acid expression levels of T helper type 2 cytokines IL-4 and IL-13.
|
28279075 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that eupatilin suppressed the levels of serum immunoglobulin E (IgE), interleukin-4 (IL-4), and AD involved cytokines, such as tumor necrosis factor α (TNFα), interferon-γ (IFN-γ), IL-1β, and thymic stromal lymphopoietin (TSLP), IL-33, IL-25 and increased the levels of filaggrin and loricrin in the oxazolone-induced AD-like mouse model.
|
29353040 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, AS significantly suppressed serum levels of histamine and IgE, while Bu-OH significantly suppressed serum levels of histamine, IgE, thymic stromal lymphopoietin (TSLP), interleukin (IL)-4 and IL-6, and DEQA significantly suppressed serum levels of histamine, IgE, TSLP and IL-4 in DNFB-induced AD mice.
|
29740850 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, stechamone attenuated DNCB-induced increases in IL-4 (an inflammatory T<sub>H</sub>2 cytokine) expression and in serum IgE levels in our murine model of AD.
|
29653408 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrated that SeMet supplementation suppresses AD-like skin lesions in BALB/c mice and inhibits the expression of total IgE and IL-4.
|
30175780 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent studies have indicated that serum levels of squamous cell carcinoma antigen (SCCA) 1 and 2 induced by type 2 cytokines such as IL-4 and IL-13, are increased in patients with atopic dermatitis (AD).
|
28734739 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human mAb targeting the IL-4 Rα subunit, blocks signaling of both IL-4 and IL-13 and is the first biologic to be approved for the treatment of moderate-to-severe AD in adult patients.
|
29122151 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-4 plays an important role in the pathogenesis of atopic dermatitis (AD) by dysregulating many key factors at the transcriptional level.
|
30239037 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13, appears to significantly decrease the risk for skin infections and eczema herpeticum in adults with moderate-to-severe AD.
|
28987493 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We also investigated the inhibitory capacity of WIKIM30 on the development of 2,4-dinitrochlorobenzene-induced atopic dermatitis (AD), a Th2-dominant allergic disease in mice.Oral administration of <i>L. sakei</i> WIKIM30 significantly reduced AD-like skin lesions and serum immunoglobulin E and IL-4 levels while decreasing the number of CD4<sup>+</sup> T cells and B cells and the levels of Th2 cytokines (IL-4, IL-5, and IL-13) in peripheral lymph nodes and enhancing Treg differentiation and IL-10 secretion in mesenteric lymph nodes.
|
30154801 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human anti-interleukin 4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of Type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately-controlled moderate-to-severe atopic dermatitis in adults.
|
29193016 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor alpha, inhibits the signals of interleukin-4 and interleukin-13, and has also shown significant efficacy in patients with moderate-to-severe atopic dermatitis (AD), while the effect of it on adverse events remains controversial.
|
29182975 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mimicking acute AD by exposing DCs to IL-4 and LTAs revealed that IL-4 significantly and uniformly suppressed epi-LTA-induced cytokine production, keeping the IL-12p70-to-IL-10 ratio balanced.
|
29569765 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, the therapeutic effect of anti-IL-4 receptor α against AD was not as high as that of IL-17 blockage against psoriasis, which implies a modification of the disease spectrum by non-Th2-type cytokine axes in AD.
|
29518197 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking the IL-4 and IL-13 pathway, is one of the first biologics that has been developed for AD.
|
30181845 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Barrier dysfunction is an important feature of atopic dermatitis (AD) in which IL-4 and IL-13, signature type 2 cytokines, are involved.
|
29528494 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
The JFE improved AD symptoms in both oxazolone- and DNCB-induced AD mice by accelerating skin barrier recovery function and suppressing the overproduction of serum immunoglobulin E (IgE) and interleukin 4 (IL-4).
|
29258854 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
A defective barrier and microbial dysbiosis drive an interleukin 4 (IL-4) loop that underlies atopic dermatitis, while in psoriasis, disordered keratinocyte signaling and predisposition to type 17 responses drive a pathogenic IL-17 loop.
|
30446754 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent studies have revealed the involvement of T helper (Th)2 cytokines including Interleukin 4 (IL-4) in the pathogenesis of AD.
|
29649105 |
2018 |